A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptors
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The receptor for glucagon‐like peptide‐1 (GLP‐1) can be activated by both its physiological hormone and a peptide discovered in the venom of the Gila Monster, exendin‐4, which shows promise as an antidiabetic agent. Exendin‐4 displays receptor‐binding properties not observed for GLP‐1. Firstly, exendin‐4 can be truncated by up to eight residues at its N‐terminus without a significant loss of affinity. Secondly, exendin‐4 maintains high affinity for the isolated N‐terminal domain of the receptor, suggesting that exendin‐4 makes additional contacts with this domain of the receptor, which nullify the requirement for ligand–receptor interactions involving the extracellular loops and/or transmembrane helices of the receptor's core domain. In order to further understand the nature of the receptor–peptide interaction, a variety of full length and truncated peptide analogues were used to quantify the contribution of each distinct region of exendin‐4 and GLP‐1 to receptor affinity. Our data show that, for both exendin‐4 and GLP‐1, the primary interaction is between the putative helical region of the peptide and the extracellular N‐terminal domain of the receptor. However, we demonstrate that the contribution to receptor affinity provided by the N‐terminal segment of GLP‐1 is greater than that of exendin‐4, while the C‐terminal nine residue extension of exendin‐4, absent in GLP‐1, forms a compensatory interaction with the N‐terminal domain of the receptor. We describe a peptide–receptor binding model to account for these data. British Journal of Pharmacology (2003) 140, 339–346. doi:10.1038/sj.bjp.0705453
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“Unfortunately, the half-life of GLP1 itself is very short due to dipeptidyl peptidase IV (DPP IV) cleavage of the first two N-terminal residues (Kieffer et al., 1995), and therefore the discovery of more physiologically stable GLP-1 receptor agonists is necessary.”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“…physiological role of GLP-1 is in maintaining blood sugar levels via a glucose-dependent mechanism, the GLP-1 receptor (GLP-1R) is a potential target for glucose-dependent therapeutic agents designed to treat hyperglycaemia resulting from type II diabetes (Gutniak et al., 1992; Moller, 2001).”
BackgroundDesigning a 20-residue protein
Neidigh, J. W., Fesinmeyer, R. M., & Andersen, N. H. (2002) · Nature Structural Biology · doi:10.1038/nsb798 · Cited by 793 · cited 3×
“While, at first sight, the data from the chimaeric peptides of Montrose-Rafizadeh et al. (1997) appear to be contradictory with our data, they are in fact entirely compatible once the more recently determined information on the structure of EX4 is taken into account (Neidigh et al., 2001; 2002).”
BackgroundResultStructural requirements for biological activity of glucagon‐like peptide‐I
MOJSOV, S. (1992) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1992.tb00309.x · Cited by 33 · cited 1×
“Truncation of GLP-1 at its C-terminus also results in a reduction of receptor affinity (Mojsov, 1992).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“A two-domain model has emerged and suggests that GLP-1 binds via its a-helical and C-terminal motifs to the N-terminal ECD of GLP-1R followed by the activation of GLP-1R through binding of the N-terminal residues of GLP-1 with the transmembrane helices and extracellular loops of the receptor [401,421,422].”
BackgroundGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Self-citationMechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors
Hoare, S. R. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03370-2 · Cited by 379
Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295
The structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Self-citation
Metadata
- Authors
- Al‐Sabah, S., & Donnelly, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2003-09
- Volume
- 140
- Issue
- 2
- Pages
- 339-346
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1982077841
- Cited by
- 100
- References
- 5
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.